This page shows the latest Vosevi news and features for those working in and with pharma, biotech and healthcare.
The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral response (SVR) for 12 or more weeks post-treatment. ... John Milligan, president and chief executive officer, Gilead, said: “The authorisation
The US FDA has approved Gilead Sciences' triple drug therapy Vosevi to treat hepatitis C Virus (HCV) as a back-up therapy for patients who can't eliminate the virus with ... The FDA has cleared the new product for all the most common HCV genotypes (1-6)
virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir). ... The CHMP notes that "both Maviret and Vosevi are active against all genotypes of the virus and with some differences between
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
No results were found
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...